AU2005244115A1 - Pharmaceutical solution formulations containing 17-AAG - Google Patents

Pharmaceutical solution formulations containing 17-AAG Download PDF

Info

Publication number
AU2005244115A1
AU2005244115A1 AU2005244115A AU2005244115A AU2005244115A1 AU 2005244115 A1 AU2005244115 A1 AU 2005244115A1 AU 2005244115 A AU2005244115 A AU 2005244115A AU 2005244115 A AU2005244115 A AU 2005244115A AU 2005244115 A1 AU2005244115 A1 AU 2005244115A1
Authority
AU
Australia
Prior art keywords
volume
component
amount
aag
cremophor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005244115A
Other languages
English (en)
Inventor
Peter J. Licari
Ziyang Zhong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kosan Biosciences Inc
Original Assignee
Kosan Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kosan Biosciences Inc filed Critical Kosan Biosciences Inc
Publication of AU2005244115A1 publication Critical patent/AU2005244115A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2005244115A 2004-05-11 2005-05-06 Pharmaceutical solution formulations containing 17-AAG Abandoned AU2005244115A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US57021504P 2004-05-11 2004-05-11
US60/570,215 2004-05-11
US11/123,570 2005-05-05
US11/123,570 US20050256097A1 (en) 2004-05-11 2005-05-05 Pharmaceutical solution formulations containing 17-AAG
PCT/US2005/016010 WO2005110398A2 (en) 2004-05-11 2005-05-06 Pharmaceutical solution formulations containing 17-aag

Publications (1)

Publication Number Publication Date
AU2005244115A1 true AU2005244115A1 (en) 2005-11-24

Family

ID=35310196

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005244115A Abandoned AU2005244115A1 (en) 2004-05-11 2005-05-06 Pharmaceutical solution formulations containing 17-AAG

Country Status (10)

Country Link
US (1) US20050256097A1 (enExample)
EP (1) EP1744743A2 (enExample)
JP (1) JP2007537258A (enExample)
AU (1) AU2005244115A1 (enExample)
BR (1) BRPI0511036A (enExample)
CA (1) CA2565583A1 (enExample)
IL (1) IL178689A0 (enExample)
MX (1) MXPA06012935A (enExample)
RU (1) RU2382643C2 (enExample)
WO (1) WO2005110398A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090197852A9 (en) * 2001-08-06 2009-08-06 Johnson Robert G Jr Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor
KR20070044805A (ko) 2004-04-15 2007-04-30 키아스마, 인코포레이티드 생물학적 장벽 투과를 촉진시킬 수 있는 조성물
CA2604424A1 (en) * 2005-04-29 2006-11-09 Kosan Biosciences Incorporated Method of treating multiple myeloma using 17-aag or 17-ag or a prodrug of either in combination with a proteasome inhibitor
EP1874296A4 (en) * 2005-04-29 2010-06-30 Kosan Biosciences Inc METHOD FOR THE TREATMENT OF SEVERAL MYELOMES USING 17-AAG OR 17-AG OR PRODRUGS OR ALL
US7648976B2 (en) * 2005-11-23 2010-01-19 Bristol-Myers Squibb Company 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
US20090042847A1 (en) * 2005-11-23 2009-02-12 Kosan Biosciences Incorporated 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
US20070167422A1 (en) * 2006-01-18 2007-07-19 Yu Kwok S Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
EP2073803B1 (en) 2006-10-12 2018-09-19 Astex Therapeutics Limited Pharmaceutical combinations
WO2008055386A1 (fr) * 2006-11-10 2008-05-15 Shenzhen Shengeryimei Biotech Co., Ltd. Composition pharmaceutique hydrosoluble pour injection de 17-allyl amino-17-déméthoxy geldanamycine (17-aag)
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
EP2121957A4 (en) * 2007-01-26 2010-11-10 Kosan Biosciences Inc MACROLACTAMES OBTAINED BY MODIFIED BIOSYNTHESIS
KR20100057007A (ko) * 2007-07-09 2010-05-28 글렌 에스. 권 치료제의 마이셀 캡슐화
BRPI0819081A8 (pt) * 2007-10-08 2016-08-30 Fovea Pharmaceuticals Sa Formulação oftálmica aquosa, processo para preparar a mesma, e, método para inibir, tratar ou prevenir doenças oculares e doença ou condição relacionada, em um paciente em necessidade de tal tratamento
US20090258869A1 (en) * 2008-02-08 2009-10-15 The Regents Of The University Of California Methods and compounds for treatment or prevention of substance-related disorders
ES2629131T3 (es) 2008-09-17 2017-08-07 Chiasma Inc. Composiciones farmacéuticas y métodos de suministro relacionados.
EP2480207B1 (en) 2009-09-25 2016-11-09 Wisconsin Alumni Research Foundation Micelle encapsulation of therapeutic agents
EP2547333B1 (en) * 2010-03-18 2017-08-23 Innopharma, Inc. Stable bortezomib formulations
US8945627B2 (en) 2011-05-05 2015-02-03 Wisconsin Alumni Research Foundation Micelles for the solubilization of gossypol
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
US10898582B2 (en) 2014-12-11 2021-01-26 University Of Utah Research Foundation Bi-functional allosteric protein-drug molecules for targeted therapy
RS66942B1 (sr) 2015-02-03 2025-07-31 Amryt Endo Inc Lečenje akromegalije oralnim oktreotidom
JP2018008922A (ja) * 2015-08-04 2018-01-18 わかもと製薬株式会社 ステロイド白内障の予防及び治療
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US553153A (en) * 1896-01-14 Type-writing machine
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
US6262022B1 (en) * 1992-06-25 2001-07-17 Novartis Ag Pharmaceutical compositions containing cyclosporin as the active agent
US5932556A (en) * 1995-09-17 1999-08-03 Tam; Robert C Methods and compositions for regulation of CD28 expression
JP4713698B2 (ja) * 1997-03-05 2011-06-29 スージェン， インク． 疎水性薬剤の処方
US20030044434A1 (en) * 1997-07-29 2003-03-06 Ping Gao Self-emulsifying formulation for lipophilic compounds
US6121323A (en) * 1997-12-03 2000-09-19 3M Innovative Properties Company Bishydroxyureas
US5925776A (en) * 1997-12-24 1999-07-20 Schein Pharmacetical, Inc. Polyethoxylated castor oil, process of making the same and formulations thereof
US6682758B1 (en) * 1998-12-22 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Water-insoluble drug delivery system
ATE289801T1 (de) * 1998-12-22 2005-03-15 Us Health Verabreichungssystem für wasserunlösliche arzneistoffe
TW471968B (en) * 1999-08-25 2002-01-11 Committee On Chinese Medicine Solamargine pharmaceutical composition for killing cancer cells
US20020037855A1 (en) * 2000-05-05 2002-03-28 Fritz Stanislaus Stabilized medicament containing cysteinyl derivatives
WO2002009696A1 (en) * 2000-07-28 2002-02-07 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
EA006759B1 (ru) * 2000-10-31 2006-04-28 Бёрингер Ингельхайм Фармасьютиклз, Инк. Пероральные лекарственные самоэмульгирующиеся композиции ингибиторов протеазы из класса пиранонов
US7025992B2 (en) * 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations
EP1373215B1 (en) * 2001-03-30 2006-07-26 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Geldanamycin derivatives useful for treating cancer
US7015328B2 (en) * 2001-05-16 2006-03-21 Cytovia, Inc. Substituted coumarins and quinolines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US6962944B2 (en) * 2001-07-31 2005-11-08 Arqule, Inc. Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
US6653319B1 (en) * 2001-08-10 2003-11-25 University Of Kentucky Research Foundation Pharmaceutical formulation for poorly water soluble camptothecin analogues
US8071133B2 (en) * 2001-08-20 2011-12-06 Stiefel Laboratories, Inc. Oral dosage forms of water insoluble drugs and methods of making the same
DE60233150D1 (de) * 2001-10-19 2009-09-10 Isotechnika Inc Neue cyclosporin-analoge mikroemulsionsvorkonzentrate
WO2003053400A1 (en) * 2001-12-19 2003-07-03 Alza Corporation Formulation & dosage form for the controlled delivery of therapeutic agents
JP2005519884A (ja) * 2001-12-19 2005-07-07 アルザ・コーポレーシヨン 親水性高分子の経口生利用度を向上させる調合物および投薬形態物
US6803046B2 (en) * 2002-08-16 2004-10-12 Bracco International B.V. Sincalide formulations
US7649006B2 (en) * 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof

Also Published As

Publication number Publication date
BRPI0511036A (pt) 2007-11-27
WO2005110398A3 (en) 2006-05-04
IL178689A0 (en) 2007-02-11
JP2007537258A (ja) 2007-12-20
RU2382643C2 (ru) 2010-02-27
US20050256097A1 (en) 2005-11-17
EP1744743A2 (en) 2007-01-24
RU2006143666A (ru) 2008-06-20
WO2005110398A2 (en) 2005-11-24
CA2565583A1 (en) 2005-11-24
MXPA06012935A (es) 2007-01-26

Similar Documents

Publication Publication Date Title
US20050256097A1 (en) Pharmaceutical solution formulations containing 17-AAG
US20100203114A1 (en) Micelle encapsulation of therapeutic agents
US20050261263A1 (en) Benzoquinone ansamycins
EP1628667B1 (en) Method for treating diseases using hsp90-inhibiting agents in combination with antimitotics
EP1628657A2 (en) Method for treating diseases using hsp90-inhibiting agents in combination with platinum coordination complexes
EP1420747A2 (en) Benzoquinone ansamycins
WO2004108080A2 (en) Method for treating diseases using hsp90-inhibiting agents in combination with immunosuppressants
WO2005000214A2 (en) Method for treating diseases using hsp90-inhibiting agents in combination with antibiotics
US6887993B1 (en) 11-O-methylgeldanamycin compounds
US6855705B1 (en) 11-O-methylgeldanamycin compounds
US20070167422A1 (en) Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
CA2596867A1 (en) Pharmaceutical formulations containing 17-allylamino-17-demethoxygeldanamycin
US7648976B2 (en) 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
CN100490800C (zh) 含17-aag的药物溶液制剂
NZ551111A (en) Pharmaceutical solution formulations containing 17-AAG in a vehicle comprising ethanol, polyethoxylated castor oil, and a third component
US20090042847A1 (en) 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations
KR20070018117A (ko) 17-ａａｇ를 함유하는 약제학적 용제
EP1682514A1 (en) 11- o-methylgeldanamycin compounds
US6875863B1 (en) 11-O-methylgeldanamycin compounds
CN118984706A (zh) 一种取代的1-(3,3-二氟哌啶-4-基)-咪唑并[4,5-c]喹啉-2-酮衍生物的晶型、其盐的晶型、制备方法及应用
JP2005515164A (ja) ベンゾキノンアンサマイシン
CN101578267A (zh) 17-烯丙氨基-17-脱甲氧格尔德霉素多晶型物和制剂

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application